EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments

Evi Gkikopoulou, Christos-Chrysovalantis Syrigos, Ioanna Mantogiannakou, Chrysa-Eleni Petraki, Melina Stathopoulou, Melina Dragolia, Vagelis Rinotas iD, Vasileios Ntafis iD, Martina Rauner, Eleni Douni iD

International Journal of Molecular Sciences · 22.05.2025 · 26 (11) · 4990

DOI: 10.3390/ijms26114990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2025. Verfasst von Evi Gkikopoulou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Fleming 34, 16672 Vari, Greece. Hauptthemen laut MEDLINE: RANK Ligand, Bone Neoplasms, Breast Neoplasms, Bone Density Conservation Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union and Greek national funds through the Operational Program Competi-tiveness, Entrepreneurship and Innovation under the call RE-SEARCH-CREATE-INNOV…, Hellenic Foundation for Research and Innovation (HFRI) under the 3rd Call for HFRI PhD Fellowships, DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast formation and bone resorption, in osteolytic conditions such as osteoporosis and bone metastases. However, its role in metastasis progression remains incompletely understood. Herein, we examined whether the overexpression of human RANKL in transgenic mice (TgRANKL) affects their susceptibility to breast cancer bone metastasis compared to their wild-type (WT) littermates. Bone metastasis was induced by injecting EO771 mouse mammary adenocarcinoma cells into the caudal artery of syngeneic WT and TgRANKL mice. RANKL overexpression led to an earlier onset and increased burden of bone metastasis in EO771-bearing TgRANKL mice compared to WT mice. It also exacerbated the bone destruction caused by metastasis-associated osteolysis. The prophylactic inhibition of RANKL activity with denosumab, a monoclonal antibody targeting human RANKL, prevented osteolysis and significantly reduced the incidence and progression of bone metastases in TgRANKL mice. However, the therapeutic denosumab treatment had no effect on metastasis incidence or tumor burden, although it alleviated osteolysis. The treatment with zoledronic acid, an anti-resorptive agent inhibiting osteoclast activity, yielded results similar to those of denosumab. These findings emphasize the significance of initiating early treatment with anti-resorptive agents such as denosumab or zoledronic acid to reduce the risk of bone metastasis in patients at high risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RANK LigandBone NeoplasmsBreast NeoplasmsBone Density Conservation AgentsAnimalsFemaleMiceDenosumabHumansMice, TransgenicZoledronic AcidOsteolysisOsteoclastsCell Line, TumorBone Resorption

Stichwörter der Autor:innen

RANKLbone metastasisbreast cancermouse modelspre-clinical models

Substanzen

RANK LigandDenosumabZoledronic AcidBone Density Conservation Agents

Autor:innen und Institutionen

  • Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Fleming 34, 16672 Vari, Greece.
  • Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Iera Odos 75, 11855 Athens, Greece.
  • Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming", Fleming 34, 16672 Vari, Greece.
  • Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, University Medical Center, Technical University of Dresden, 01307 Dresden, Germany.

ORCID-Profile: Vagelis Rinotas, Vasileios Ntafis, Eleni Douni

Förderung

  • European Union and Greek national funds through the Operational Program Competi-tiveness, Entrepreneurship and Innovation under the call RE-SEARCH-CREATE-INNOV…
  • Hellenic Foundation for Research and Innovation (HFRI) under the 3rd Call for HFRI PhD Fellowships
  • DFG
  • Operational Program for Competitiveness, Entrepreneurship, and Innovation
  • Hellenic Foundation for Research and Innovation (HFRI)

Zitieren

APA

Gkikopoulou, E., Syrigos, C. C., Mantogiannakou, I., Petraki, C. E., Stathopoulou, M., Dragolia, M., Rinotas, V., Ntafis, V., Rauner, M., & Douni, E. (2025). RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments. International Journal of Molecular Sciences, 26(11), 4990. https://doi.org/10.3390/ijms26114990

Vancouver

Gkikopoulou E, Syrigos CC, Mantogiannakou I, Petraki CE, Stathopoulou M, Dragolia M, et al. RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments. International Journal of Molecular Sciences. 2025;26(11):4990. doi:10.3390/ijms26114990

BibTeX
@article{Gkikopoulou2025,
  author = {Gkikopoulou, Evi and Syrigos, Christos-Chrysovalantis and Mantogiannakou, Ioanna and Petraki, Chrysa-Eleni and Stathopoulou, Melina and Dragolia, Melina and Rinotas, Vagelis and Ntafis, Vasileios and Rauner, Martina and Douni, Eleni},
  title = {RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {11},
  pages = {4990},
  doi = {10.3390/ijms26114990}
}
Kostenlos starten →